Investor

Arch

Last cheque observed May 2026; 26 cheques on record.

Email

Deploying nowHedge fundWebsite unconfirmed

Series ASeries BSeries CSoftwareWealth Management

Deploying now
100%of best year1cheques in 12 months, 26 on record
Since the last cheque169days00hrs00min00sec
Median round$44MRounds led0 of 26Mostly inUnited States, 88%
Pitch Arch

Arch highlights

  1. 01

    1 cheques in the last 12 months

  2. 02

    Mostly Series A and Series B: 68% of its rounds

What they do

Type
Hedge fund (from a list, unverified)
Cheque size
Not stated
Sectors
SoftwareWealth Management
Cold pitches
Not stated

A website was listed for this organisation, but we could not confirm it belongs to the firm that wrote these cheques. Either the site never mentions them, or it turned out to be a different company sharing the name. We show neither it nor anything read from it. Tell us the right one.

The record

Every round we can evidence, newest first26 appearances

  1. 2026

    1 round

  2. May
    NovellaSeries A · US · Ventureburn$21MWith 7 others
  3. 2019

    4 rounds

  4. May
    Verve TherapeuticsSeries A · US · FinSMEs$59MWith 3 others
  5. Apr
    908 DevicesSeries E · US · FinSMEs$18MWith 7 others
  6. Mar
    Beam TherapeuticsSeries B · US · FinSMEs$135MWith 7 others
  7. Mar
    ErascaSeries A · US · FinSMEs$64MWith 2 others
  8. 2018

    10 rounds

  9. Aug
    Magnolia NeuroscienceSeries A · US · FinSMEs$31MWith 10 others
  10. Jul
    OmniomeSeries B · US · FinSMEs$60MWith 6 others
  11. Jul
    Gossamer BioSeries B · US · Biospace$230MWith 4 others
  12. Jul
    AgBiomeSeries C · US · FinSMEs$65MWith 5 others
  13. Jun
    Just BiotherapeuticsSeries B · CN · FinSMEs$35MWith 4 others
  14. Jun
    CytrellisSeries B · US · FinSMEs$29MWith 3 others
  15. May
    Brii BioCN · FinSMEs$260MWith 5 others
  16. May
    CStoneSeries B · CN · FinSMEs$260MWith 13 others
  17. May
    Luna DNAUS · FinSMEs$4.0MWith 4 others
  18. Mar
    UnitySeries C · US · FinSMEs$55MWith 11 others
  19. 2017

    11 rounds

  20. Nov
    CodiakSeries C · US · FinSMEs$77MWith 8 others
  21. Nov
    ImmusanTSeries C · US · FinSMEs$40MWith 1 other
  22. Oct
    KSQ TherapeuticsUS · FinSMEs$76MWith 2 others
  23. Sept
    LifeMine TherapeuticsSeries A · US · FinSMEs$55MWith 6 others
  24. Jul
    Rodeo TherapeuticsSeries A · US · FinSMEs$5.9MWith 7 others
  25. May
    AiraSeries B · US · FinSMEs$12MWith 4 others
  26. Mar
    908 DevicesGrowth · US · FinSMEs$20MWith 6 others
  27. Mar
    OncoResponseSeries A · US · FinSMEs$23MWith 8 others
  28. Mar
    AledadeSeries D · US · Baltimore$20MWith 3 others
  29. Mar
    BoragenSeries A · US · FinSMEs$10MWith 9 others
  30. Jan
    Scholar RockSeries C · US · FinSMEs$47MWith 7 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 1 person at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

Who they invest alongside

The investors most often in the same rounds as Arch. A count of rooms they were both in, not a relationship either has claimed.

Alexandria Real Estate EquitiesVC firm6rounds togetherFidelityVC firm4rounds together6 Dimensions CapitalVC firm3rounds togetherBiomatics CapitalVC firm3rounds togetherBoyu CapitalPrivate equity3rounds togetherCasdin CapitalVC firm3rounds togetherEcoR1 CapitalPrivate equity3rounds togetherGoldbell GroupGrowth equity3rounds togetherGoogle VenturesCorporate VC3rounds togetherAbbVieCorporate VC2rounds togetherAltitude Life Science VenturesVC firm2rounds togetherBlue Pool CapitalPrivate equity2rounds together

Recently backed

The latest companies Arch put money into.

Verve Therapeutics$59M · May 2019908 Devices$18M · Apr 2019Beam Therapeutics$135M · Mar 2019Erasca$64M · Mar 2019Gossamer Bio$230M · Jul 2018AgBiome$65M · Jul 2018

Quick answers about Arch

What does Arch invest in?

Arch invests most often at Series A and Series B (68% of the rounds on record), in sectors such as Software and Wealth Management.

How active is Arch?

26 investments on record, 1 of them in the last 12 months. The most recent was in May 2026.

What has Arch invested in recently?

Its most recent investments on record: Novella (Series A, May 2026), Verve Therapeutics (Series A, May 2019) and 908 Devices (Series E, Apr 2019).

How big are Arch's cheques?

The median round it joins is $44M.

Does Arch lead rounds?

Rarely, if at all: none of its 26 investments on record names it as the lead.

Where does Arch invest?

Most of the companies it backs are in the United States (88%) and China (12%).

Is Arch investing now?

Yes: it is actively investing, with 1 investments in the last 12 months.

Who does Arch invest alongside?

Most often Alexandria Real Estate Equities (6 rounds together), Fidelity (4 rounds together) and 6 Dimensions Capital (3 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it